Article Text

THU0086 Seropositivity and response to RTX: Data from the cererra collaboration
  1. K. Chatzidionysiou1,
  2. E. Lie2,
  3. E. Nasonov3,
  4. G. Lukina3,
  5. M. Hetland4,
  6. U. Tarp5,
  7. I. Ancuta6,
  8. K. Pavelka7,
  9. D. Nordström8,
  10. C. Gabay9,
  11. H. Canhao10,
  12. M. Tomsic11,
  13. P. van Riel12,
  14. J. Gomez-Reino13,
  15. T. Kvien14,
  16. R. van Vollenhoven1
  1. 1Clintrid, Rheumatology Department, Karolinska Institute, Stockholm, Sweden
  2. 2Dep of Rheumatology, Diakonhjemmet Hosp, Oslo, Norway
  3. 3Arbiter, Inst of Rheumatology, Moscow, Russian Federation
  4. 4Copenhagen Univ Hosp at Glostrup, on behalf of DANBIO, Copenhagen
  5. 5Aarhus Univ Hosp, Aarhus, Denmark
  6. 6Cantacuzino Hosp, Bucharest, Romania
  7. 7Charles Univ Hosp, Prague, Czech Republic
  8. 88ROB-FIN Helsinki Univ Central Hosp, Helsinki, Finland
  9. 9SCQM registry, Univ Hosp of Geneva, Geneva, Switzerland
  10. 10Hosp Santa Maria, Lisbon, on behalf of the Rheumatic Diseases Portuguese Register, Lisbon, Portugal
  11. 11Univ Medical Center, Ljubljana, Ljubljana, Slovenia
  12. 12Radboud Univ Nijmegen Medical Centre, Nijmegen, Netherlands
  13. 13Hosp Clinico Univ De Santiago, Santiago, Spain
  14. 14Diakonhjemmet Hosp, Oslo, Norway


Background Predictors of response to biologic therapy in rheumatoid arthritis (RA) are needed to achieve a more individualized therapy. Seropositivity has been associated with better response to rituximab (RTX).

Objectives To assess the 6-month response to the first RTX course in RA according to RF and ACPA status.

Methods Ten European registries submitted anonymized datasets from RA patients who had started RTX, and datasets were pooled and analysed. Chi-square test for comparison of categorical variables and t-test for continuous data were used. Predictors of response were identified by logistic regression analysis.

Results 3266 patients were included in the cohort. 79.9% of patients were RF (+) (2041 out of 2553) and 73.2% were ACPA (+) (877 out of 1198). 718 patients were double positive (DP) and 147 double negative (DN). 2200 patients were RF (+) and/or ACPA (+). Improvements of DAS28 (ΔDAS28) at 6 months were significantly better for RF (+) than RF (–) patients as well as for ACPA (+) than ACPA (–), DP vs. DN and RF and/or ACPA (+) vs. DN (table 1). A significantly higher percentage of ACPA (+) and DP patients achieved EULAR Good Response at 6 months compared to ACPA (–) and DN, respectively (table 1). The completeness of data was very similar for seropositive and seronegative patients, with the percentage of missing data at 6 months being approximately 50% in all groups. A significantly higher percentage of seronegative patients received retreatment by 6 months than seropositive patients. In univariate analyses adjusted for age and gender ACPA positivity (OR=2.03, p=0.016) and DP (OR=2.43, p=0.03) but not RF positivity (OR=1.53, p=0.07) predicted EULAR good response to therapy with RTX at 6 months after the first treatment.

Table 1. Clinical outcomes at 6 months for RTX treated patients according to RF and ACPA status

Conclusions In this large observational cohort of RA patients treated with RTX, seropositive patients achieved significantly greater reductions in DAS28 at 6 months compared to seronegative patients. Baseline ACPA positivity may be a better predictor for good response to RTX than RF positivity.

Disclosure of Interest None Declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.